| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -31,929 | -22,528 |
| Depreciation and amortization | 2,698 | 1,812 |
| Allowance for credit losses | 382 | 83 |
| Inventory impairment | 267 | 177 |
| Share-based compensation | 4,667 | 3,258 |
| Non-cash interest expense | 600 | 388 |
| Loss on disposal of property and equipment | -45 | -43 |
| Accounts receivable, net | -1,384 | 2,479 |
| Inventory | 240 | 791 |
| Net investments in sales-type leases | -22 | -12 |
| Prepaid commission expense | -840 | -613 |
| Prepaid expenses and other assets | -3,813 | -3,356 |
| Accounts payable | -77 | -1,803 |
| Accrued expenses | -3,302 | -2,236 |
| Other liabilities | -223 | -320 |
| Deferred revenue | -229 | -82 |
| Net cash used in operating activities | -21,282 | -20,497 |
| Purchases of property and equipment and capitalized software | 585 | 471 |
| Net cash used in investing activities | -585 | -471 |
| Payments of debt issuance costs | 80 | - |
| Proceeds from issuance of long-term debt | 10,000 | - |
| Proceeds from the issuance of common stock-Secondary Public Offering | 20,700 | - |
| Payments of common stock offering issuance costs-Secondary Public Offering | 1,731 | - |
| Proceeds from the issuance of common stock-At Market Equity Offering Program | 8,313 | - |
| Payments of common stock offering issuance costs-At Market Equity Offering Program | 336 | - |
| Proceeds from exercises of stock options | 13 | 9 |
| Proceeds from the issuance of common stock | - | 20,700 |
| Payments of common stock offering issuance costs | - | 1,731 |
| Net cash provided by (used in) financing activities | 36,879 | 18,978 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 15,012 | -1,990 |
| Cash and cash equivalents at beginning of period | 19,459 | - |
| Cash and cash equivalents at end of period | 34,471 | - |
Neuronetics, Inc. (STIM)
Neuronetics, Inc. (STIM)